"Purpose: Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on B-10(n, alpha)Li-7 reaction, for the treatment of malignant gliomas. One of the main limitations for BNCT effectiveness is the insufficient intake of B-10 nuclei in the tumor cells. This work was aimed at investigating the use of L-DOPA as a putative enhancer for B-10-drug 4-dihydroxy-borylphenylaianine (BPA) uptake in the C6-glioma model. The investigation was first performed in vitro and then extended to the animal model. Methods and Materials: BPA accumulation in C6-glioma cells was assessed using radiowave dielectric spectroscopy, with and without L-DOPA preloading. Two L-DOPA incubation times (2 and 4 hours) were investigated, and the corresponding effects on BPA accumulation were quantified. C6-glioma cells were also implanted in the brain of 32 rats, and tumor growth was monitored by magnetic resonance imaging. Rats were assigned to two experimental branches: (1) BPA administration; (2) BPA administration after pretreatment with L-DOPA. All animals were sacrificed, and assessments of BPA concentrations in tumor tissue, normal brain, and blood samples were performed using high-performance liquid chromatography. Results: L-DOPA preloading induced a massive increase of BPA concentration in C6-glioma cells only after a 4-hour incubation. In the animal model, L-DOPA pretreatment produced a significantly higher accumulation of BPA in tumor tissue but not in normal brain and blood samples. Conclusions: This study suggests the potential use of L-DOPA as enhancer for BPA accumulation in malignant gliomas eligible for BNCT. L-DOPA preloading effect is discussed in terms of membrane transport mechanisms. (C) 2008 Elsevier Inc."

L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: A new strategy to improve BNCT efficacy

Capuani, S;Gili, T;
2008

Abstract

"Purpose: Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on B-10(n, alpha)Li-7 reaction, for the treatment of malignant gliomas. One of the main limitations for BNCT effectiveness is the insufficient intake of B-10 nuclei in the tumor cells. This work was aimed at investigating the use of L-DOPA as a putative enhancer for B-10-drug 4-dihydroxy-borylphenylaianine (BPA) uptake in the C6-glioma model. The investigation was first performed in vitro and then extended to the animal model. Methods and Materials: BPA accumulation in C6-glioma cells was assessed using radiowave dielectric spectroscopy, with and without L-DOPA preloading. Two L-DOPA incubation times (2 and 4 hours) were investigated, and the corresponding effects on BPA accumulation were quantified. C6-glioma cells were also implanted in the brain of 32 rats, and tumor growth was monitored by magnetic resonance imaging. Rats were assigned to two experimental branches: (1) BPA administration; (2) BPA administration after pretreatment with L-DOPA. All animals were sacrificed, and assessments of BPA concentrations in tumor tissue, normal brain, and blood samples were performed using high-performance liquid chromatography. Results: L-DOPA preloading induced a massive increase of BPA concentration in C6-glioma cells only after a 4-hour incubation. In the animal model, L-DOPA pretreatment produced a significantly higher accumulation of BPA in tumor tissue but not in normal brain and blood samples. Conclusions: This study suggests the potential use of L-DOPA as enhancer for BPA accumulation in malignant gliomas eligible for BNCT. L-DOPA preloading effect is discussed in terms of membrane transport mechanisms. (C) 2008 Elsevier Inc."
2008
INFM
Istituto dei Sistemi Complessi - ISC
NEUTRON-CAPTURE THERAPY
BRAIN-BARRIER DISRUPTION
I CLINICAL-TRIAL
GLIOBLASTOMA-MULTIFORME
BORON-COMPOUNDS
File in questo prodotto:
File Dimensione Formato  
prod_2966-doc_26999.pdf

solo utenti autorizzati

Descrizione: L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: A new strategy to improve BNCT efficacy
Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 196.52 kB
Formato Adobe PDF
196.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/159080
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? ND
social impact